UK-based big pharma GlaxoSmithKline (GSK) has released its Q2 2025 results, which highlight the varying successes of its ...

GSK plc GSK reported second-quarter 2025 core earnings of $1.23 per American depositary share (ADS), which beat the Zacks ...

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...

GSK sponsors the 2025 National Senior Games to raise awareness about RSV risks and prevention for older adults through ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions in a report that ...

Data from GSK's ongoing trial published in February found a vaccine efficacy of 82.6% against RSV-related lower respiratory tract disease.

Participants in GSK's trial reported side effects more frequently than those in Pfizer’s did. The race to an RSV vaccine Several companies have been racing to secure FDA approval for RSV vaccines.

T he Food and Drug Administration on Friday expanded the approval for GSK’s vaccine to protect against respiratory syncytial virus, or RSV, authorizing its use for at-risk adults as young as 50.

GSK said Wednesday that a Phase 3 trial found Arexvy elicited an immune response in adults ages 50 to 59 who were at an increased risk for RSV due to underlying medical conditions.

GSK will market its new product under the brand name “Arexvy.” The British pharmaceutical giant said it plans to launch its new vaccine before the 2023/2024 RSV season.

However, GSK has another possible advantage in that it has shown strong efficacy when its RSV shot is jointly administered with a flu vaccine, added Dormitzer, who joined GSK in late 2021 from ...

Topline GSK shares rose on Wednesday after the pharma giant upgraded its profit guidance for the second time this year amid booming demand for its new vaccine for respiratory syncytial virus (RSV).